Ajinomoto Co., Ltd.

Tomohisa Okutsu

Hideki Matsumoto

Manabu Suzuki

Yoshiyuki Takahara

Tomoko Takeda

Takami Maekawa

Tetsuo Yano

Masaki Hashimoto

Miho Ono

Hisao Fukuda

Hideki Suzuki

Fumihiko Yokoya

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-&#x3b1;. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-&#x3b1; production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Therapeutic agent for inflammatory bowel disease and TNF-&#x3b1; production inhibitor

An isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 11, wherein the expression of said polypeptide is significant lower specifically in human livers with hepatitis compared with that in human health livers. The detection of said polypeptide expression in human liver can be used as a diagnosis for human hepatitis.

Polypeptides, use thereof and process for producing the same

Growing community of inventors

Kawasaki, Japan

Tomohisa Okutsu